Eli Lilly & Co. (LLY) disclosed that a major shareholder reported multiple open-market sales of common stock on 11/14/2025. The transactions, all coded as sales, included blocks of 103,871, 55,908, 17,567, and 949 shares at weighted average prices between $1,030.00 and $1,033.39 per share. After these trades, the reporting person directly beneficially owned 92,882,077 Eli Lilly shares. The prices reported reflect weighted averages for multiple trades within the stated price ranges.
Eli Lilly & Co (LLY) executive filed an initial statement of beneficial ownership. As of 11/07/2025, the reporting officer (EVP, President LLY Imm) directly owned 3,725 shares of common stock.
The filing also lists restricted stock units (each RSU equals one common share) covering 391 shares with dates 02/16/2026, 2,530 shares with dates 11/01/2026, 394 shares with dates 02/16/2027, and 354.091 shares with dates 02/16/2028. Ownership is reported as direct.
Eli Lilly (LLY) reported insider sales on a Form 4. On 11/13/2025, the reporting person sold 45,246 shares of common stock at a weighted average price of $1,030.21, and 1,360 shares at a weighted average price of $1,031.777. The filing notes these were executed in multiple trades within the stated price ranges. Following the transactions, the reporting person beneficially owned 93,060,372 shares.
Eli Lilly (LLY) reported an insider transaction: the company’s SVP, Finance, & CAO sold 1,000 shares of common stock at $1,010.50 per share on November 13, 2025 (transaction code S).
The filing states the trade was made under a Rule 10b5-1 trading plan adopted on November 20, 2024. Following the sale, the reporting person beneficially owns 2,839.659 shares directly and 1,727.9 shares indirectly through a 401(k).
Eli Lilly (LLY) reported insider activity on a Form 4 showing multiple open‑market sales of common stock on 11/12/2025. The transactions were executed in several tranches at weighted‑average prices disclosed in footnotes.
Following the reported sales, the reporting person beneficially owned 93,106,978 shares, held directly. Footnotes note the sales occurred across price ranges from $1,001.213 to $1,021.661, with the reporting person able to provide detailed trade breakdowns upon request.
Lilly Endowment Inc. filed a Form 144 notice to sell 295,000 shares of Eli Lilly and Company (LLY) common stock. The filing lists an aggregate market value $300,245,100, an approximate sale date of November 13, 2025, execution through Fidelity Capital Markets, and trading on NYSE, NASDAQ.
The filing notes that 945,383,757 shares of Eli Lilly common stock are outstanding. The securities to be sold trace back to a gift acquired on 02/10/1948 from the J.K. Lilly Sr. Trust, with the donor’s acquisition dated 01/21/1937 and an original amount acquired of 38,400,000 shares.
Recent sales over the past three months are disclosed, including 305,000 shares for $308,411,211.50 on 11/12/2025 and 283,131 shares for $279,347,662.01 on 11/11/2025.
Eli Lilly (LLY): Insider transaction reported. A reporting person filed a Form 4 disclosing multiple open‑market sales of Eli Lilly common stock on November 11, 2025. Each line item is coded “S” for sale and reflects a weighted average price, with individual trades occurring within the disclosed ranges.
Reported weighted average prices spanned approximately $972.269 to $999.088, with footnotes stating underlying trade ranges from $972.00 to $999.49 per share across the listed transactions. Following these sales, the reporting person beneficially owned 93,411,978 shares, held directly.
Eli Lilly & Co (LLY) reported insider transactions on 11/10/2025. The reporting person executed three open-market sales: 12,864 shares at a weighted average price of $972.168 (range $972.00–$972.87); 3,887 shares at $973.626 (range $973.025–$973.95); and 118 shares at $974.089 (range $974.065–$974.14).
After these transactions, the reporting person beneficially owned 93,695,109 shares, held directly.
Lilly Endowment Inc. filed a Form 144 to sell 305,000 shares of Eli Lilly and Company (LLY) common stock, with an approximate sale date of November 12, 2025. The designated broker is J.P. Morgan Securities LLC, and the filing lists NYSE, NASDAQ as the exchanges.
The notice also details recent activity: examples include 300,000 shares sold on November 3, 2025 for $266,648,940 and 283,131 shares sold on November 11, 2025 for $279,347,662.01. The shares to be sold trace back to an earlier acquisition noted as a gift dated February 10, 1948 from the J.K. Lilly Sr. Trust.
Eli Lilly (LLY) CEO David A. Ricks reported a code G transfer of 24,750 shares of common stock on 11/10/2025 at a stated price of $0. Following the transaction, he directly owns 515,166.167 shares.
He also reports indirect holdings, including 6,685 shares by the David A. Ricks 2025 GRAT, 54,117 shares by the 2022 GRAT, 300 shares by a trust, 68,656 shares by the David A. Ricks SLAT, and 7,305.09 shares in a 401(k). The footnotes note a transfer of 6,685 shares to the 2025 GRAT on September 9, 2025.